JP2018526330A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526330A5 JP2018526330A5 JP2017567174A JP2017567174A JP2018526330A5 JP 2018526330 A5 JP2018526330 A5 JP 2018526330A5 JP 2017567174 A JP2017567174 A JP 2017567174A JP 2017567174 A JP2017567174 A JP 2017567174A JP 2018526330 A5 JP2018526330 A5 JP 2018526330A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- cdr
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 355
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 264
- 238000000034 method Methods 0.000 claims description 48
- 239000012472 biological sample Substances 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 7
- 102000016917 Complement C1 Human genes 0.000 claims description 6
- 108010028774 Complement C1 Proteins 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 6
- 230000003844 B-cell-activation Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 238000002203 pretreatment Methods 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185362P | 2015-06-26 | 2015-06-26 | |
| US62/185,362 | 2015-06-26 | ||
| PCT/US2016/039087 WO2016210172A1 (en) | 2015-06-26 | 2016-06-23 | Methods of treating autoimmune and alloimmune disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526330A JP2018526330A (ja) | 2018-09-13 |
| JP2018526330A5 true JP2018526330A5 (cg-RX-API-DMAC7.html) | 2019-07-25 |
| JP6963509B2 JP6963509B2 (ja) | 2021-11-10 |
Family
ID=57585852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567174A Active JP6963509B2 (ja) | 2015-06-26 | 2016-06-23 | 自己免疫障害及び同種免疫障害の処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20180169240A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3313417A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6963509B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180020296A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108348600A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016282782A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2990662A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA038567B1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1254030A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL256424B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2017016835A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016210172A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2912065A4 (en) | 2012-10-25 | 2016-10-19 | True North Therapeutics Inc | ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF |
| RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| HK1259251A1 (zh) | 2015-04-06 | 2019-11-29 | Bioverativ Usa Inc. | 人源化抗c1s抗体及其使用方法 |
| DK3448419T5 (da) * | 2016-04-29 | 2024-09-09 | Pfizer | Interferon-beta-antistoffer og anvendelser deraf |
| EP3525583B8 (en) | 2016-10-12 | 2025-09-10 | Bioverativ USA Inc. | Anti-c1s antibodies and methods of use thereof |
| JP7731196B2 (ja) | 2017-11-14 | 2025-08-29 | 中外製薬株式会社 | 抗Ｃ１ｓ抗体および使用方法 |
| WO2020230834A1 (en) | 2019-05-15 | 2020-11-19 | Chugai Seiyaku Kabushiki Kaisha | An antigen-binding molecule, a pharmaceutical composition, and a method |
| WO2021075479A1 (en) * | 2019-10-16 | 2021-04-22 | Chugai Seiyaku Kabushiki Kaisha | An antibody, a pharmaceutical composition, and a method |
| CN116724236A (zh) * | 2020-08-06 | 2023-09-08 | 美国比奥维拉迪维股份有限公司 | 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳 |
| EP4337332A2 (en) | 2021-07-13 | 2024-03-20 | Mabwell Therapeutics Inc. | Anti-c1s antibodies and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001013945A1 (en) * | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
| ES2614274T3 (es) * | 2002-09-06 | 2017-05-30 | Alexion Pharmaceuticals, Inc. | Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5 |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| WO2009132058A2 (en) * | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| CN102597005A (zh) * | 2009-06-23 | 2012-07-18 | 阿雷克森制药公司 | 与补体蛋白质结合的双特异性抗体 |
| EP2912065A4 (en) * | 2012-10-25 | 2016-10-19 | True North Therapeutics Inc | ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF |
| RS63212B1 (sr) * | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
-
2016
- 2016-06-23 CA CA2990662A patent/CA2990662A1/en active Pending
- 2016-06-23 IL IL256424A patent/IL256424B2/en unknown
- 2016-06-23 EP EP16815332.8A patent/EP3313417A4/en active Pending
- 2016-06-23 JP JP2017567174A patent/JP6963509B2/ja active Active
- 2016-06-23 US US15/739,622 patent/US20180169240A1/en not_active Abandoned
- 2016-06-23 EA EA201890106A patent/EA038567B1/ru unknown
- 2016-06-23 HK HK18112887.1A patent/HK1254030A1/zh unknown
- 2016-06-23 WO PCT/US2016/039087 patent/WO2016210172A1/en not_active Ceased
- 2016-06-23 MX MX2017016835A patent/MX2017016835A/es unknown
- 2016-06-23 AU AU2016282782A patent/AU2016282782A1/en not_active Abandoned
- 2016-06-23 KR KR1020187002518A patent/KR20180020296A/ko active Pending
- 2016-06-23 CN CN201680044603.9A patent/CN108348600A/zh active Pending
-
2017
- 2017-12-19 MX MX2023002021A patent/MX2023002021A/es unknown
-
2021
- 2021-09-08 US US17/469,625 patent/US20220249664A1/en not_active Abandoned
-
2022
- 2022-08-12 AU AU2022215307A patent/AU2022215307B2/en not_active Expired - Fee Related
-
2024
- 2024-12-03 US US18/966,631 patent/US20250295768A1/en active Pending